Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for Trigeminal Neuropathic Pain
NCT05142228Phase 2Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2022
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Trigeminal neuralgia (TN) comparing Erenumab-aooe with Placebo (2 arms). Primary endpoint: Change of >= 30% Reduction in the Monthly (28 Days) Average Pain Score From Baseline to Visit 4 at 16 weeks. Started May 2022; status: terminated.
02
Drugs
erenumab
03
Conditions
Trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT05142228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142228.